ONCOLOGY Vol 26 No 3 | Oncology

Lymphedema: Separating Fact From Fiction

March 15, 2012

Given the abundance of breast cancer data, this review will focus on breast cancer–related lymphedema. However, the principles and controversies discussed are relevant regardless of the type of malignancy to which the lymphedema is attributed.

Metastatic Colorectal Cancer: A Curable Disease

March 13, 2012

Combined-modality therapy has rendered disease-free an increasing number of patients who were previously considered to be incurable. Still, despite myriad advances in imaging, and in surgical and therapeutic modalities, many patients who undergo resection of limited metastatic disease with curative intent ultimately relapse.

Renal Cancer Therapeutics: Now What?

March 13, 2012

The development of vascular endothelial growth factor (VEGF) pathway inhibitors and mammalian target of rapamycin (mTOR) inhibitors for the treatment of renal cancer is a real success story.

Metastatic RCC: Moving Towards a Chronic Disease

March 13, 2012

The article by Posadas and Figlin on systemic therapy in advanced renal cell carcinoma (RCC) provides a very interesting and comprehensive review of our current knowledge concerning the treatment of RCC.

Lymphedema: Still a Problem Without an Answer

March 12, 2012

It is ironic that we were asked to comment on the article by Dr. McLaughlin in this issue of ONCOLOGY. A few months ago, one of us (LKJ) was attending a patient in the breast clinic who had recovered well from a lumpectomy with sentinel node biopsy followed by completion axillary lymph node dissection (ALND).

Oncology Smartphone Applications: Perspectives From a Researcher/Community-Based Hematologist/Oncologist and a Physician Reviewer of Medical Apps

March 09, 2012

The surge in availability of apps for every possible purpose is not limited to Apple but has also occurred with apps for the BlackBerry, for Google's Android platform, and for a number of other devices. The authors discuss their experience with apps that are relevant, directly or indirectly, to the oncology practice for both the iPhone and Android smartphones.

Oral Therapies and Food: To Eat or Not to Eat?

February 25, 2012

The treatment of cancer is shifting to increasingly more oral pills. Most oncology drug labels recommend taking the pills while fasting though often there is evidence that food increases bioavailability of the medication as much as four-fold.

Semuloparin Helps Prevent Thromboembolic Events in Patients Receiving Chemotherapy

February 22, 2012

Semuloparin, an ultra-low molecular weight heparin reduces the probability that a cancer patient undergoing chemotherapy has a thromboembolic event by 64%. The results from the phase III trial also show that the benefit is not accompanied by an increase in major bleeding, a potential side effect of semuloparin.

FDA Grants Imatinib (Gleevec) Full Approval for Adjuvant Treatment of GIST

February 07, 2012

The FDA has granted imatinib full approval as an adjuvant treatment following surgical removal of CD117-positive gastrointestinal stromal tumors in adult patients. This comes after results from a phase III trial showed that patients taking imatinib for 36 months had a 5-year overall survival of 92%, compared to 82% for those patients who took the drug for the standard 12 months of treatment.

New Way to Predict Prostate Cancer Severity-Size of Prostate

February 01, 2012

It is still difficult to gauge the probability that a low-risk prostate cancer patient may be upgraded to a higher prostate cancer stage. Researchers at Vanderbilt University Medical Center have now determined that smaller prostates were more likely to evolve into more serious, aggressive disease.